Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

Core Insights - Anixa Biosciences is focused on cancer treatment and prevention, featuring its Chairman and CEO, Dr. Amit Kumar, on the Water Tower Research Healthcare Happenings podcast to discuss positive clinical trial data for its breast cancer vaccine and ovarian cancer CAR-T therapy [1] Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company specializing in cancer treatment and prevention [1] - The company's therapeutic portfolio includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology [1] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [1] Technology and Collaboration - The CAR-T technology used by Anixa is differentiated by its mechanism, where the natural ligand of the FSHR receptor binds to tumor cells instead of using an antibody fragment [1] - Anixa partners with renowned research institutions to explore emerging technologies for further development and commercialization [1] Financial and Future Outlook - Dr. Kumar discussed the financial condition of the company and future plans during the podcast, indicating a focus on advancing their clinical programs [1]